Christopher Missling | President and CEO
Anavex Life Sciences

Christopher Missling, President and CEO, Anavex Life Sciences

Dr. Missling, President and CEO of Anavex™, has over 20 years of healthcare industry experience within large pharmaceutical companies, the biotech industry and investment banking. Prior to joining Anavex, he served as the Chief Financial Officer of Curis and ImmunoGen. In addition, at Aventis (now Sanofi), Dr. Missling worked as head of financial planning on all aspects of financial strategy and M&A. His career experience also includes working as an investment banker in the healthcare practice at Deutsche Bank, serving pharmaceutical, biotech, and diagnostic companies, as well as serving as the head of healthcare investment banking at Brimberg & Co. in New York. Dr. Missling has an MS and PhD from the University of Munich in Chemistry and an MBA from Northwestern University Kellogg School of Management.

Appearances:



World Orphan Drug Congress USA 2018 - Rare Disease Advocacy Track Day 1 @ 11:30

Empowered educated patients influencing pre-clinical development and working with industry to optimize drug discovery

  • Patient groups role guiding research, disease understanding, supporting pre-clinical development and follow up experiments 
  • Driving translational research and the influence on formulation, routes to delivery and overall clinical development 
  • Effective partnerships between advocacy and industry to expand collaborations that can support enrollment and physician engagement

back to speakers